Your browser doesn't support javascript.
loading
Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model.
Zorn, Julie A; Wheeler, Matthew L; Barnes, Ralston M; Kaberna, Jim; Morishige, Winse; Harris, Marek; Huang, Richard Y-C; Lohre, Jack; Chang, Yu Ching; Chau, Bryant; Powers, Kathleen; Schindler, Ian; Neradugomma, Naveen; Thomas, Winston; Liao, Xiaoyun; Zhou, Yinhan; West, Sean M; Wang, Feng; Kotapati, Srikanth; Chen, Guodong; Yamazoe, Sayumi; Kosenko, Anastasia; Dollinger, Gavin; Sproul, Tim; Rajpal, Arvind; Strop, Pavel.
Afiliación
  • Zorn JA; Discovery Biotherapeutics, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Wheeler ML; Immuno Oncology Discovery, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Barnes RM; Discovery Biotherapeutics, Bristol Myers Squibb, Redwood City, 94063, USA. ralston.barnes@bms.com.
  • Kaberna J; Immuno Oncology Discovery, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Morishige W; Discovery Biotherapeutics, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Harris M; Immuno Oncology Discovery, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Huang RY; Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Lawrenceville, 08543, USA.
  • Lohre J; In Vivo Pharmacology, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Chang YC; Translational Research, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Chau B; Discovery Biotherapeutics, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Powers K; Discovery Biotherapeutics, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Schindler I; Discovery Biotherapeutics, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Neradugomma N; Discovery Biotherapeutics, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Thomas W; Discovery Biotherapeutics, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Liao X; Translational Research, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Zhou Y; Discovery Biotherapeutics, Bristol Myers Squibb, Redwood City, 94063, USA.
  • West SM; Discovery Biotherapeutics, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Wang F; Discovery Biotherapeutics, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Kotapati S; Discovery Biotherapeutics, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Chen G; Analytical Development & Attribute Sciences, Biologics Development, Bristol Myers Squibb, New Brunswick, 08903, USA.
  • Yamazoe S; Discovery Biotherapeutics, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Kosenko A; Discovery Biotherapeutics, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Dollinger G; Discovery Biotherapeutics, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Sproul T; In Vivo Pharmacology, Bristol Myers Squibb, Redwood City, 94063, USA.
  • Rajpal A; Genentech, South San Francisco, 94080, USA.
  • Strop P; Biologics Discovery, Tallac Therapeutics, Burlingame, 94010, USA.
Sci Rep ; 12(1): 3530, 2022 03 03.
Article en En | MEDLINE | ID: mdl-35241687
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Anticuerpos Biespecíficos / Neoplasias Límite: Animals / Humans Idioma: En Revista: Sci Rep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Anticuerpos Biespecíficos / Neoplasias Límite: Animals / Humans Idioma: En Revista: Sci Rep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos